Fatih Safa Erenay1, Oguzhan Alagoz1, Ritesh Banerjee2, Robert R Cima3. 1. Department of Industrial and Systems Engineering, University of Wisconsin–Madison, Madison, Wisconsin (Department of Management Sciences, University of Waterloo Waterloo (FSE, OA) 2. Formerly at Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. Current affiliation is Analysis Group, Inc., Boston, Massachusetts (RB) 3. Colon and Rectal Surgery, Mayo Graduate School of Medicine, Mayo Clinic, Rochester, Minnesota (RRC)
Abstract
OBJECTIVES: Some aspects of the natural history of metachronous colorectal cancer (MCRC), such as the rate of progression from adenomatous polyp to MCRC, are unknown. The objective of this study is to estimate a set of parameters revealing some of these unknown characteristics of MCRC. METHODS: The authors developed a computer simulation model that mimics the progression of MCRC for a 5-year period following the treatment of primary colorectal cancer (CRC). They obtained the inputs of the simulation model using longitudinal data for 284 CRC patients from the Mayo Clinic, Rochester. RESULTS: Five-year MCRC incidence and all-cause mortality were 7.4% and 12.7% in the patient cohort, respectively. Statistical analysis showed that 5-year MCRC incidence was associated with gender (P = 0.05), whereas both all-cause and CRC-related mortalities were associated with age (P < 0.001 and P = 0.01). Estimated annual probabilities of progression from adenomatous polyp to MCRC and from MCRC to metastatic MCRC were 0.14 and 0.28, respectively. Annual probabilities of mortality after MCRC and metastatic MCRC treatments were estimated to be 0.06 and 0.26, respectively. The estimated annual probability of mortality due to undetected MCRC was 0.16. CONCLUSIONS: The results imply that MCRC, especially in women, may be more common than suggested by previous studies. In addition, statistics derived from the clinical data and results of the simulation model indicate that gender and age affect the progression of MCRC.
OBJECTIVES: Some aspects of the natural history of metachronous colorectal cancer (MCRC), such as the rate of progression from adenomatous polyp to MCRC, are unknown. The objective of this study is to estimate a set of parameters revealing some of these unknown characteristics of MCRC. METHODS: The authors developed a computer simulation model that mimics the progression of MCRC for a 5-year period following the treatment of primary colorectal cancer (CRC). They obtained the inputs of the simulation model using longitudinal data for 284 CRC patients from the Mayo Clinic, Rochester. RESULTS: Five-year MCRC incidence and all-cause mortality were 7.4% and 12.7% in the patient cohort, respectively. Statistical analysis showed that 5-year MCRC incidence was associated with gender (P = 0.05), whereas both all-cause and CRC-related mortalities were associated with age (P < 0.001 and P = 0.01). Estimated annual probabilities of progression from adenomatous polyp to MCRC and from MCRC to metastatic MCRC were 0.14 and 0.28, respectively. Annual probabilities of mortality after MCRC and metastatic MCRC treatments were estimated to be 0.06 and 0.26, respectively. The estimated annual probability of mortality due to undetected MCRC was 0.16. CONCLUSIONS: The results imply that MCRC, especially in women, may be more common than suggested by previous studies. In addition, statistics derived from the clinical data and results of the simulation model indicate that gender and age affect the progression of MCRC.
Authors: Kendra L Schwartz; Heather Crossley-May; Fawn D Vigneau; Karl Brown; Mousumi Banerjee Journal: Cancer Causes Control Date: 2003-10 Impact factor: 2.506
Authors: Sidney Winawer; Robert Fletcher; Douglas Rex; John Bond; Randall Burt; Joseph Ferrucci; Theodore Ganiats; Theodore Levin; Steven Woolf; David Johnson; Lynne Kirk; Scott Litin; Clifford Simmang Journal: Gastroenterology Date: 2003-02 Impact factor: 22.682
Authors: David Z J Chu; Kari Chansky; David S Alberts; Frank L Meyskens; Cecilia M Fenoglio-Preiser; Saul E Rivkin; Glenn M Mills; Jeffrey K Giguere; Gary E Goodman; James L Abbruzzese; Scott M Lippman Journal: Ann Surg Oncol Date: 2003-10 Impact factor: 5.344
Authors: Mucahit Cevik; Mehmet Ali Ergun; Natasha K Stout; Amy Trentham-Dietz; Mark Craven; Oguzhan Alagoz Journal: Med Decis Making Date: 2015-10-15 Impact factor: 2.583
Authors: Mark Roberts; Louise B Russell; A David Paltiel; Michael Chambers; Phil McEwan; Murray Krahn Journal: Value Health Date: 2012 Sep-Oct Impact factor: 5.725
Authors: Jessica M Franklin; Sebastian Schneeweiss; Jennifer M Polinski; Jeremy A Rassen Journal: Comput Stat Data Anal Date: 2014-04 Impact factor: 1.681
Authors: Fernando Alarid-Escudero; Richard F MacLehose; Yadira Peralta; Karen M Kuntz; Eva A Enns Journal: Med Decis Making Date: 2018-10 Impact factor: 2.583
Authors: Harindra Jayasekara; Jeanette C Reece; Daniel D Buchanan; Christophe Rosty; S Ghazaleh Dashti; Driss Ait Ouakrim; Ingrid M Winship; Finlay A Macrae; Alex Boussioutas; Graham G Giles; Dennis J Ahnen; Jan Lowery; Graham Casey; Robert W Haile; Steven Gallinger; Loic Le Marchand; Polly A Newcomb; Noralane M Lindor; John L Hopper; Susan Parry; Mark A Jenkins; Aung Ko Win Journal: Int J Cancer Date: 2016-05-09 Impact factor: 7.316